1. Extracorporeal Blood Adsorber Product Introduction The Extracorporeal Blood Adsorber is a device designed to remove specific substances from the patient's blood outside of the body, utilizing a specialized adsorption material that selectively targets and binds to these substances. This process allows for the effective elimination of toxins, drugs, and waste products that may be harmful to the patient's health. The adsorber is engineered to maintain the integrity of the blood cells and plasma, ensuring that only the targeted substances are removed, thus preserving the patient's overall blood composition. The system is highly efficient, enabling rapid treatment and recovery, and is adaptable to various patient conditions, making it a versatile tool in medical care. Figure1: Extracorporeal Blood Adsorber Product Picture Extracorporeal Blood Adsorber Based on or includes research from QYResearch: 2. Leading Manufacturer in the industry 1) Fresenius Medical Care Fresenius Medical Care is a global medical technology enterprise centered on the treatment of kidney diseases. Its business revolves around providing comprehensive clinical products, services, and solutions for patients with chronic renal failure and other kidney-related diseases. This encompasses hemodialysis machines, peritoneal dialysis systems, disposable medical consumables, infusion solutions and pharmaceuticals, combined with a network of diagnosis and treatment support services to assist hospitals and dialysis centers in optimizing blood purification treatment processes. The company's products are utilized globally in hospitals, dialysis centers, and critical care environments, supporting routines including conventional dialysis, continuous kidney replacement therapy (CKRT), therapeutic plasma exchange, and other extracorporeal blood purification modalities. Concurrently, through clinical collaboration, it strengthens therapy integration and innovation to enhance treatment quality and patient care experience. Official product presentations indicate that its consumables and systems are designed to promote high standards in dialysis and purification therapy and to provide supportive solutions for blood purification applications in acute and critical care. Regarding extracorporeal hemoperfusion cartridges, Fresenius Medical Care offers different types of perfusion components within its critical care and acute blood purification product portfolio to support extracorporeal blood purification therapies. The company, through partnerships, introduces and distributes resin-based perfusion cartridges such as CytoSorb. This component utilizes porous polymer resin beads to adsorb inflammatory mediators, cytokines, and other middle-molecular-weight substances from the blood during extracorporeal circulation, thereby assisting in controlling severe inflammatory responses and toxic substance accumulation. Simultaneously, Fresenius Medical Care has expanded its portfolio with pathogen adsorption perfusion devices introduced through third-party technology collaborations, such as the Seraph 100 Affinity Adsorption Filter. This device, employing activated carbon or functional surface adsorption materials, removes pathogens from the bloodstream via extracorporeal circulation for auxiliary purification treatment in states of infectious blood diffusion. Furthermore, in certain markets, the company offers composite material perfusion components. These components integrate different adsorption media and membrane technologies to meet complex clinical purification needs, for example, by enhancing middle-molecular substance removal capacity in scenarios like sepsis or high-toxin clearance, and are compatible with its overall purification platforms. The aforementioned resin-based, activated carbon-based, and composite material hemoperfusion cartridges are designed as single-use components, aiming to deliver an efficient and safe operational experience for single-session extracorporeal circulation purification therapies, supporting extracorporeal hemoperfusion treatment in critical care. CytoSorb® is an extracorporeal hemoperfusion cartridge, a single-use, non-pyrogenic, sterilized medical device, specifically designed as a third-generation blood adsorption device for critically ill patients. Its core consists of highly porous polystyrene-divinylbenzene copolymer beads, with an average particle size of approximately 450 μm and a pore size of 0.8–5 nm, providing an exceptionally large adsorption surface area (approximately 45,000–46,000 m²/300 mL cartridge). It operates via physical adsorption through a direct hemoperfusion mechanism. Adsorption relies on hydrophobic interactions, concentration dependency, and molecular size selectivity (effectively targeting hydrophobic middle-molecular-weight substances <55–60 kDa), enabling the efficient removal of various pro-inflammatory cytokines (such as IL-6, TNF-α, etc.), bilirubin, myoglobin, and other toxic mediators, while restricting the entry of larger molecules. It is particularly indicated for patients with multiple organ dysfunction accompanied by high cytokine/toxin levels, such as in sepsis (including septic shock), cytokine storm, acute liver failure, rhabdomyolysis, and vasoplegic shock. It rapidly reduces the load of inflammatory mediators and toxins in circulation, mitigates excessive inflammatory responses, improves hemodynamics, protects organ function, and helps prevent or reverse organ failure. The recommended blood flow rate is 150–700 mL/min (minimum 100 mL/min), with a maximum single-cartridge use time of 24 hours. It can operate in an independent perfusion mode or be compatibly integrated with extracorporeal circuits such as continuous kidney replacement therapy (CKRT/CRRT, e.g., multiFiltrate PRO systems) and ECMO, serving as a supplement to achieve multi-organ support. Its clinical advantage lies in providing a unique, non-selective yet highly efficient extracorporeal purification capability for middle-molecular toxins that are difficult to remove via conventional dialysis, significantly reducing inflammatory burden and improving treatment outcomes. It is the flagship adsorption consumable originally developed by CytoSorbents Corporation (USA) on the Fresenius Medical Care acute blood purification platform (with Fresenius distributing/integrating it in regions such as the EU). 2) NorrDia NorrDia is a medical technology enterprise focused on blood purification and kidney care. Its business encompasses providing extracorporeal blood purification therapies, equipment, and consumable solutions for clinical scenarios such as chronic and acute renal failure, and critical care. By integrating specialized capabilities accumulated from industry experience with companies like Gambro, Baxter, and Nikkiso, the company develops CRRT (Continuous Renal Replacement Therapy) platforms, hemodialysis consumables, related tubing and accessories, while promoting extracorporeal purification treatment methods suitable for critically ill patients. This is complemented by clinical services and training support to assist healthcare professionals in improving efficacy and safety in critical illness treatment. NorrDia's product portfolio includes CRRT monitoring systems, filters, bloodlines, and various consumables, and it is also involved in auxiliary technologies and supporting services related to renal replacement and blood purification, reflecting its comprehensive product layout and clinical support capabilities in the field of blood purification. Regarding its product layout for extracorporeal hemoperfusion cartridges, within the domain of Disposable Acute Blood Purification Consumables, NorrDia primarily provides adsorption components and related configuration support for extracorporeal blood purification therapies. In the functional category of perfusion cartridges, this includes perfusion cartridge products based on resin adsorption technology, such as the Efferon® LPS hemoadsorption component. This single-use, non-pyrogenic, and gamma-irradiated sterilized consumable selectively adsorbs lipopolysaccharides, cytokines, myoglobin, and endogenous and exogenous toxic substances from the blood. It is suitable for severe purification situations such as bacteremia or elevated endotoxemia, providing support for the purification management of acute inflammatory responses. Currently, publicly available information does not clearly indicate that NorrDia maintains independent product lines for activated carbon-based perfusion cartridges or composite material perfusion cartridges. Its Disposable Acute Blood Purification Consumables, apart from resin-based perfusion cartridges, also cover other extracorporeal circulation purification components such as ECCO2R (extracorporeal CO2 removal) systems, which do not fall under the typical hemoperfusion cartridge category. These single-use perfusion consumables, when used in conjunction with extracorporeal circulation purification devices, enable the adsorption of specific molecules and removal of toxins during the patient's extracorporeal circulation. This supports clinical control of intermediate metabolites and inflammatory mediators, thereby enhancing the functional effectiveness of critical blood purification treatments. NorrDia Efferon® LPS is a third-generation extracorporeal hemoadsorption cartridge. As a Disposable Acute Blood Purification Consumable, it is a single-use, non-pyrogenic, gamma-irradiated medical device specifically designed for direct hemoperfusion. Its core utilizes a multimodal polymeric adsorbent – macroporous/mesoporous spherical beads based on a hypercrosslinked styrene-divinylbenzene copolymer, with covalently immobilized LPS-selective ligands on their surface. This enables selective and highly efficient adsorption of lipopolysaccharides (LPS, i.e., bacterial endotoxins). Simultaneously, leveraging the inherent pore structure of the polymeric matrix, it non-selectively adsorbs excessive cytokines (such as pro-inflammatory mediators like IL-6), myoglobin, cellular debris, and endogenous and exogenous toxic substances. It is particularly indicated for patients with Gram-negative sepsis (including septic shock), critical endotoxemia (elevated blood endotoxin levels), and cytokine storm syndrome. By simultaneously removing endotoxins (PAMPs) and endogenous inflammatory mediators (DAMPs), it rapidly restores physiological balance, improves hemodynamics, mitigates multiple organ failure, and enhances survival rates. It is compatible and can be integrated with CRRT systems (e.g., Aquarius+), enabling true extracorporeal organ support. In clinical application, it significantly reduces inflammatory burden, shortens shock duration, and lowers medical costs, embodying the core value of "Restore Balance. Improve Outcomes. Reduce Costs." It represents an innovative third-generation consumable for precision blood purification in sepsis. 3) Chongqing SWS Hemodialysis Care Chongqing Shanwaishan Blood Purification Technology Co., Ltd. is a Chinese medical device enterprise specializing in comprehensive blood purification solutions. Its business revolves around the research and development, production, sales, and clinical services of blood purification equipment and consumables. The company's product portfolio encompasses various purification equipment such as hemodialysis machines, continuous blood purification devices (e.g., CRRT), and blood perfusion machines. Concurrently, its wholly-owned subsidiary, Chongqing Tianwaitian Biotechnology Co., Ltd., is responsible for the development and manufacturing of consumables including dialysate filters, disposable extracorporeal circulation circuits, disposable hemodialysis circuits, and perfusion cartridges, forming a complete industry chain layout from equipment to consumables. Through the operation support of its dialysis center intelligent management system and chain hemodialysis centers, it provides comprehensive blood purification services for clinical scenarios such as chronic renal failure, acute kidney injury, poisoning, and multiple organ failure. Official materials indicate that the company's products are utilized by numerous major hospitals and medical institutions and are exported to many countries and regions globally, offering systematic blood purification treatment support for patients with kidney disease and critically ill patients. Regarding the status of its extracorporeal hemoperfusion cartridges, Shanwaishan's blood purification consumable system includes disposable blood perfusion cartridges. These perfusion cartridges are developed by its wholly-owned subsidiary, Chongqing Tianwaitian Biotechnology Co., Ltd., and have obtained Class III medical device registration certificates issued by the National Medical Products Administration. As single-use consumables designed for use in conjunction with blood purification devices, they are intended to be used in combination with dialyzers for extracorporeal circulation hemoperfusion treatment. Through adsorption or filtration mechanisms, they remove medium and large molecular endogenous toxic substances (represented by β₂-microglobulin, etc.) from the patient's blood, thereby assisting in reducing the toxin burden and improving treatment efficacy during the clinical purification process. Official product information indicates that this disposable blood perfusion cartridge possesses design features such as coated adsorbent particles and optimized biocompatibility, aimed at enhancing adsorption performance and reducing complication risks. Publicly available information does not show Shanwaishan clearly distinguishing other functional categories such as activated carbon-based perfusion cartridges or composite material perfusion cartridges. Its perfusion cartridges primarily belong to the disposable blood perfusion cartridge type and constitute a significant component of the company's blood purification consumables portfolio, used for the removal of specific toxic substances during extracorporeal circulation purification procedures. The Tianwaitian TN Series Disposable Hemoperfusion Cartridges are a type of extracorporeal hemoperfusion cartridge. As a Class III single-use, sterile medical device, it is specifically designed as a single-use apparatus for hemoperfusion treatment. Its core employs high-performance adsorption particles treated with coating technology (resin based on secondary cross-linking technology), offering excellent biocompatibility and significantly reduced complications. With a specific surface area exceeding 1000 m²/g, it provides an exceptionally large effective adsorption area and robust clearance performance. Its regulated pore density technology confers a relatively specific adsorption capability, making it particularly efficient at targeting medium and large molecular endogenous toxins represented by β₂-microglobulin (β₂-MG), while simultaneously adsorbing various uremia-related protein-bound toxins and other middle-molecular toxins. A novel spherical shell and cover structure ensures uniform blood flow, greatly reducing the probability of clotting and hemolysis during treatment. The small blood chamber capacity reduces extracorporeal priming blood volume and lowers treatment risks. The preservation solution is neutral to avoid metabolic acidosis, and the steam sterilization process ensures it is non-toxic, residue-free, and offers higher biocompatibility. It is suitable for critically ill patients with multiple organ dysfunction in conditions such as acute and chronic renal failure (especially maintenance hemodialysis patients with β₂-MG accumulation), prevention of uremic complications, drug/poison intoxication, and liver failure. Through direct hemoperfusion, it rapidly removes pathogenic factors, improves uremic symptoms, reduces the risk of cardiovascular events, delays the progression of complications, and enhances prognosis. It can be used independently or compatibly integrated with blood purification devices (such as hemodialysis machines, CRRT systems), serving as a supplement to achieve precise extracorporeal purification. It embodies the core advantages of domestic high-performance perfusion consumables: proprietary core technology + steam sterilization + efficient adsorption targeting β₂-MG. It represents the flagship extracorporeal hemoperfusion consumable within Shanwaishan's fully integrated industry chain layout, signifying the developmental direction of adsorption technology in hemoperfusion cartridges. 4) Beijing Zksk Technology Zhongke Shengkang is a national high-tech enterprise integrating research and development, production, and sales of medical devices. Its core business spans multiple medical fields including blood purification, digestive endoscopy, orthopedic consumables, and protective products. Through proprietary intellectual property rights and international quality system certifications, the company promotes the entry of its products into both domestic and international clinical markets. In the field of blood purification, the company has developed consumable categories including disposable blood perfusion cartridges and disposable blood filters, providing clinical support for dialysis centers, hospital blood purification treatments, and critical care scenarios. Its product system, supported by modern R&D and production platforms, relevant medical device registration certificates, and patented technologies, is dedicated to enhancing the safety and clinical operability of blood purification treatments. Official materials indicate that Zhongke Shengkang has obtained medical device registration certificates from the National Medical Products Administration for its blood purification consumables, demonstrating that its products comply with regulatory requirements for clinical application. Regarding the product category of extracorporeal hemoperfusion cartridges, Beijing Zhongke Shengkang Technology primarily provides disposable blood perfusion cartridges as key components within its blood purification consumable portfolio. These perfusion cartridges are designed to be used in conjunction with blood purification devices, guiding patient blood through an extracorporeal circuit into the internal adsorption medium of the cartridge to achieve the removal of specific molecules or toxic components. According to information released by the National Medical Products Administration, Zhongke Shengkang's disposable blood perfusion cartridges have obtained medical device registration approval. These perfusion consumables typically employ synthetic adsorption materials to capture endogenous and exogenous metabolites, poisons, or drug residues from the blood, providing support during the blood purification treatment process. Publicly available information does not clearly indicate that the company distinguishes different functional subcategories such as resin-based perfusion cartridges, activated carbon-based perfusion cartridges, or composite material perfusion cartridges. Its disposable blood perfusion consumables primarily refer to extracorporeal circulation perfusion cartridges as single-function components. These cartridges are clinically used in extracorporeal purification pathways to assist in the removal of target molecules and constitute an important part of the company's blood purification consumable system. Zhongke Shengkang's disposable blood perfusion cartridges (ZKHP 80, ZKHP 100, ZKHP 130, ZKHP 230, ZKHP 330) are a type of extracorporeal hemoperfusion cartridge. As a Class III single-use, sterile medical device, it is specifically designed as a single-use apparatus for blood purification treatment. Its core employs macroporous polystyrene neutral resin as the adsorbent, treated with collodion coating to enhance biocompatibility and adsorption selectivity. The housing is composed of polycarbonate end caps/caps/cylinders, silicone rubber sealing plugs/sealing rings, polypropylene mesh frames, and nylon filter screens. It is filled with preserved water for injection and sterilized via electron beam radiation. Through a direct hemoperfusion mechanism, it utilizes the physical adsorption of macroporous adsorption resin (relying on pore structure, hydrophobic interactions, and surface charge modulation) to efficiently and targetedly remove protein-bound toxins from the blood, particularly uremia-related toxins represented by indoxyl sulfate (IS), while also adsorbing other endogenous/exogenous middle-molecular toxins. It is especially suitable for patients with end-stage renal disease (ESRD), to be used in conjunction with blood purification devices (such as hemodialysis machines or CRRT systems) for hemoperfusion treatment, or combined with dialyzers to achieve an extracorporeal circulation hemoperfusion + dialysis mode. By simultaneously clearing protein-bound toxins, it improves uremic symptoms, reduces the risk of cardiovascular events, enhances quality of life, and delays the progression of complications. Its clinical advantage lies in providing supplementary purification capability for protein-bound toxins that are difficult to effectively remove via conventional dialysis. It features good biocompatibility, low clotting risk, and simple operation. It represents a domestically produced high-performance extracorporeal circulation hemoperfusion consumable targeting the removal of protein-bound toxins in ESRD within the company's blood purification device series, embodying the core values of precise adsorption, safety, and reliability. 3. Key Market Trends, Opportunity, Drivers and Restraints 1) Market Trends The development trend of extracorporeal blood adsorbers is now distinctly characterized by the integrated evolution of technological systems, the deepening of clinical applications, and the intelligent coordination of device capabilities. At the technological level, extracorporeal blood adsorbers no longer exist as isolated consumables but are systematically embedded within the holistic platform of blood purification. Through modular interfaces and standardized circuit designs, they achieve high compatibility with extracorporeal circulation hosts, enabling flexible switching and combined operation of adsorption therapy within the same extracorporeal circulation system, thereby enhancing clinical operational efficiency and reducing treatment complexity. At the clinical level, the focus of their application is steadily expanding from traditional scenarios of specific toxin removal towards comprehensive supportive therapy for critically ill patients. Particularly in extracorporeal circulation treatment scenarios such as inflammatory mediator clearance, immune modulation, and multi-organ function support, extracorporeal blood adsorbers are positioned as key functional components. This expansion of indications, in turn, drives technological demands for higher biocompatibility, stronger selective adsorption capacity, and more stable extracorporeal circulation performance. At the device capability level, intelligent management of the operational status of extracorporeal blood adsorbers has become a significant direction. Through data acquisition and algorithmic support, dynamic optimization of hemodynamic parameters, anticoagulation strategies, and adsorption timing is achieved. Coupled with remote monitoring and centralized management functions, this makes adsorption therapy more controllable and predictable during extracorporeal circulation processes, thereby improving safety and the level of personalized treatment. Overall, extracorporeal blood adsorbers are evolving from single-function consumables into highly integrated, intelligently coordinated core therapeutic modules within extracorporeal circulation systems, with their technological form and clinical value advancing simultaneously. 5) Opportunities The development opportunities for extracorporeal blood adsorbers primarily stem from the structural expansion of clinical demand, improvements in reimbursement and market access environments, and the long-term incremental space created by the upgrading of healthcare systems in emerging regions. From the clinical perspective, the continuous increase in the population of patients with chronic kidney disease and critical illnesses has been repeatedly confirmed by the World Health Organization and public health authorities in various countries. The demand from such patients for the removal of toxins, inflammatory mediators, and endogenous harmful substances during extracorporeal circulation therapy is becoming increasingly prominent. This continually reinforces the clinical value of extracorporeal blood adsorbers in critical care support and comprehensive treatment, creating numerous application scenarios that are not yet fully met. From the institutional perspective, major healthcare markets such as the United States and the European Union, through official medical insurance policy documents and announcements from health regulatory authorities, continue to signal a more open reimbursement stance towards advanced extracorporeal circulation technologies. Some extracorporeal circulation-related consumables have been included or piloted for inclusion in reimbursement scopes, which objectively reduces the economic barriers for hospitals to adopt extracorporeal blood adsorbers and enhances the clinical acceptance and willingness for standardized use of new adsorption protocols. From the regional perspective, emerging economies such as China and India have explicitly stated in government plans and official documents from health departments their goals to enhance blood purification and critical care capabilities. With the acceleration of healthcare infrastructure construction and the proliferation of extracorporeal circulation technology in tertiary hospitals and regional medical centers, the demand for extracorporeal blood adsorbers as key consumables amplifies in sync with the expansion of extracorporeal treatment capacity. Simultaneously, driven by official healthcare investments and international cooperation projects, some countries in Southeast Asia and Latin America are gradually developing the conditions to introduce extracorporeal blood adsorption therapy, providing a continuously unfolding incremental market space for such products. 6) Challenges The development of extracorporeal blood adsorbers faces multiple practical obstacles, first reflected in the overall treatment cost pressure. This has been repeatedly mentioned in public discussions by health authorities and public healthcare systems in many countries. Extracorporeal circulation therapy itself relies on high-standard equipment and single-use, high-value consumables. As a key functional component, the use of adsorbers inevitably increases the overall cost of a single extracorporeal circulation treatment, limiting its promotion in regions with constrained medical resources and healthcare systems with limited payment capabilities. Secondly, at the technical and clinical levels, extracorporeal blood adsorbers impose extremely high demands on the blood compatibility and stability of the adsorption materials. Regulatory agencies and academic institutions have pointed out that if materials induce coagulation reactions, inflammatory activation, or blood cell damage during extracorporeal circulation, it will directly affect treatment safety. This poses ongoing challenges for material research and development, process control, and long-term clinical validation. Simultaneously, as this technology remains a relatively novel approach in some extracorporeal circulation applications, there are still differences among clinicians in their understanding of its indication boundaries, efficacy assessment, and timing of use, requiring long-term evidence-based medical accumulation and support from standardized training. In terms of regulation and market access, the European Union’s new Medical Device Regulation and the review system of the U.S. Food and Drug Administration have clearly raised requirements in official documents regarding the safety, traceability, and clinical evidence for high-risk extracorporeal circulation consumables. When changes occur in the design, materials, or production processes of extracorporeal blood adsorbers, re-registration or supplementary clinical data is often required, significantly extending the product launch cycle and increasing compliance costs. Meanwhile, as commonly mentioned in corporate annual reports and announcements, changes in the international trade environment and geopolitical factors have introduced uncertainties in the supply of key raw materials and core components, compelling manufacturers of extracorporeal blood adsorbers to mitigate risks through supply chain restructuring, localized production, or multi-channel procurement. However, this process itself leads to increased costs and operational complexity, further intensifying the practical challenges for industry development. 7) Industry Entry Barriers The extracorporeal blood adsorber industry presents significant and systematic barriers to entry for new entrants, with these barriers first evident at the technology and research and development level. Public materials from regulatory agencies and companies in multiple countries clearly indicate that the core competitiveness of extracorporeal blood adsorbers lies not merely in structural design or extracorporeal circulation engineering, but in the safety, stability, and blood compatibility of the adsorption materials themselves. Such materials involve the long-term integration of polymer materials, surface chemistry, biocompatibility evaluation, and clinical application feedback. Even with engineering capabilities, new entrants find it difficult to achieve interdisciplinary technology accumulation and establish a sustainable product system in the short term. At the regulatory and certification level, major markets such as Europe and the United States classify extracorporeal blood adsorbers as high-risk medical devices in official regulations, requiring companies to complete systematic preclinical validation, clinical studies, and full lifecycle risk management. Even minor adjustments in design or materials may trigger supplementary reviews. This high-standard, long-cycle access mechanism creates a substantial barrier for new entrants lacking sufficient capital, time, and compliance capabilities. In terms of market and channels, the industry landscape, as repeatedly described in corporate annual reports and public news, is highly concentrated. Incumbent manufacturers have established stable relationships with major hospitals and extracorporeal circulation centers through long-term clinical collaborations, integrated solutions combining extracorporeal circulation systems with adsorption consumables, and mature global distribution networks. Even with regulatory approval, new brands struggle to quickly enter core clinical application scenarios. Meanwhile, capital and scale barriers are equally significant. Official documents and corporate disclosures generally show that from basic research and clinical trials to compliant production and global market access, extracorporeal blood adsorbers require sustained, high-intensity capital investment and rely on scaled manufacturing capabilities compliant with medical device quality management systems. This long-term capital consumption and operational complexity favor established companies with scale advantages and accumulated experience, such as Fresenius Medical Care, Baxter International, B. Braun, and Jafron Biomedical, which has built technical and clinical foundations in niche segments, thereby forming persistent and solid barriers to entry for new entrants. 4. Supply Chain Analysis 1) Upstream Market a) Adsorptive Materials Adsorptive materials directly determine the safety, effectiveness, and clinical applicability boundaries of the Extracorporeal Blood Adsorber under extracorporeal circulation conditions. Their technical characteristics and compliance status have been repeatedly emphasized by regulatory authorities in multiple countries as well as in official corporate disclosures as the foundation of product performance. Within the current technological framework, medical-grade adsorptive resins are widely regarded as the mainstream materials for Extracorporeal Blood Adsorbers. Through precise control of pore structure, surface chemical functional groups, and cross-linking methods, these resins achieve selective adsorption of medium- to large-molecular toxins and inflammatory mediators, while maintaining relatively stable blood compatibility during prolonged extracorporeal circulation. Corporate annual reports and product documentation consistently highlight that resin materials must undergo systematic biocompatibility and clinical safety validation, thereby forming high technical and regulatory entry barriers. Public disclosures by Jafron Biomedical, for example, position its HA series resins as independently developed core materials and emphasize the long-term coupling between material design, manufacturing processes, and clinical application. Activated carbon materials represent important adsorptive media in the early development stages and in specific application scenarios of Extracorporeal Blood Adsorbers. While activated carbon inherently possesses strong non-specific adsorption capacity, unmodified forms may pose blood compatibility risks. Accordingly, corporate and regulatory documents clearly require encapsulation, surface modification, or similar engineering measures to reduce particle shedding and blood irritation, which has resulted in such materials being more commonly used in short-duration extracorporeal treatments such as acute poisoning. Composite materials have evolved on the basis of these single-material systems by structurally or functionally combining resins, activated carbon, or other functional materials to meet the clearance requirements of specific toxins or inflammatory mediators. In official corporate communications, such materials are typically described as customized solutions for particular extracorporeal clinical needs, while also noting that they face higher requirements in terms of consistency control, quality validation, and regulatory review. Overall, core adsorptive materials are not only the decisive factor governing the performance of Extracorporeal Blood Adsorbers, but also constitute the upstream segment of the industry chain with the deepest technological accumulation, the most stringent regulatory requirements, and the highest difficulty of substitution. b) Composite Material Composite material systems represent a more complex and refined development direction for medical polymer materials used in Extracorporeal Blood Adsorbers, with functional polymers such as anion exchange resins serving as representative examples. By introducing specific charged functional groups into the polymer backbone, these materials are able to achieve targeted adsorption of charged toxins, inflammatory mediators, or metabolic by-products during extracorporeal circulation. Relevant regulatory explanations and official corporate materials consistently emphasize that the critical aspect of such polymer materials lies not in the adsorption principle itself, but in their long-term stability and controllability within the blood environment. Composite materials often require the integration of polymer materials with different functional layers through blending, encapsulation, or layered structural designs, in order to simultaneously meet requirements for adsorption selectivity, fluid permeability, and blood compatibility. This significantly elevates the standards for material consistency control and quality verification. As composite medical polymer materials used in Extracorporeal Blood Adsorbers frequently define the boundaries of product indications, their development and application are typically accompanied by more stringent regulatory review and clinical validation processes, thereby making them one of the upstream material categories with the highest technical barriers and regulatory thresholds within the industry chain. 8) Midstream a) Resin Adsorbent Cartridge The resin-based perfusion cartridge in an Extracorporeal Blood Adsorber refers to a medical consumable component internally filled with a synthetic polymer resin adsorbent. This type of resin adsorbent is typically a macroporous polymeric material with a microstructure characterized by high porosity and specific surface area. It primarily operates through physical adsorption and hydrophobic interactions, enabling the selective binding and removal of certain toxins, drugs, or metabolites from the blood. Synthetic resins exhibit relatively good blood compatibility and have a lesser impact on blood formed elements. Compared to early activated carbon perfusion materials, they generate fewer fine particles and are associated with reduced adverse reactions such as hemolysis, making them suitable for treating conditions like drug intoxication and endotoxin accumulation. In clinical practice, they are used in combination with other purification technologies to improve the clearance of middle-molecular-weight toxins. The advantages of resin-based perfusion cartridges lie in their strong adsorption performance for liposoluble or protein-bound molecules. Furthermore, ongoing advancements in resin materials and surface treatment technologies continue to enhance their biocompatibility and operational safety. b) Activated Charcoal Cartridge The activated carbon-based perfusion cartridge refers to a perfusion component that uses activated carbon as the primary adsorption material. Activated carbon is typically produced through the carbonization and activation of organic materials. Its porous structure provides an extremely large specific surface area, allowing it to capture small and certain middle-molecular-weight toxic substances in the blood via physical adsorption during extracorporeal blood purification. Activated carbon-based perfusion cartridges have a relatively long history and were widely used in early hemoperfusion treatments. They possess certain adsorption capabilities for drug overdoses and toxin removal. However, activated carbon that is untreated or insufficiently coated may lead to issues such as particle shedding and poor blood compatibility. In clinical applications, technologies like coating are employed to improve its biocompatibility. Activated carbon materials exhibit high adsorption efficiency for non-polar, small-molecular substances, but their clearance capability for protein-bound or high-molecular-weight substances is limited. Therefore, in modern hemoperfusion products, activated carbon-based perfusion cartridges have been progressively optimized to enhance safety and clinical applicability. c) Composite Media Cartridge The composite material perfusion cartridge refers to a consumable that combines multiple adsorption materials or adsorption mechanisms within a single perfusion component. This composite design may include the combination of resin, activated carbon, modified carbon materials, or other functional adsorption media in specific configurations to broaden the adsorption spectrum for different molecular types and improve overall adsorption efficiency. This type of perfusion cartridge aims to compensate for the limitations of single materials, achieving comprehensive removal of small, middle, and specific toxins or inflammatory mediators through composite adsorption media while enhancing blood compatibility and reducing complication risks. Composite material perfusion technology is still under development and clinical validation. Its advantages lie in the synergistic effects of multiple mechanisms and broader application scope, holding potential to expand the indications for blood purification and improve treatment outcomes in critical care purification therapies in the future. 9) Downstream a) Hospital In the hospital clinical environment, the Extracorporeal Blood Adsorber is widely utilized as a critical component in blood purification therapy for critically ill patients across multidisciplinary collaborative treatment settings such as the intensive care unit (ICU), emergency department, and nephrology department. Hemoperfusion is a blood purification technique that involves diverting the patient's blood into an extracorporeal circulation system, allowing it to come into contact with adsorption materials inside the adsorber to non-specifically adsorb and remove toxic substances, drug residues, metabolic products, and inflammatory mediators from the blood. It serves as a supplementary method to conventional dialysis for the removal of specific toxins. The application of this technology in hospitals is commonly employed for the emergency treatment of acute poisoning in critically ill patients. For example, in cases of drug overdose or organophosphorus pesticide poisoning, extracorporeal hemoperfusion can rapidly reduce the levels of toxic substances in the blood, gaining valuable time for subsequent treatments. Simultaneously, in critical conditions such as sepsis, acute kidney injury, and liver failure, the combined use of the adsorber with continuous renal replacement therapy equipment can help mitigate the load of inflammatory mediators, forming an integral part of multidisciplinary collaborative rescue protocols in comprehensive hospitals. Relying on well-established monitoring equipment, specialized blood purification teams, and stringent aseptic operation procedures, hospitals can effectively manage risks such as anticoagulation, infection prevention and control, and circulatory monitoring during extracorporeal circulation therapy, thereby enhancing the treatment safety and clinical efficacy for critically ill patients. b) Clinic In outpatient or specialized blood purification service settings such as clinics, the Extracorporeal Blood Adsorber is primarily used for chronic disease management and specific auxiliary purification treatments. Its application focuses on providing ongoing therapeutic support for patients with chronic kidney disease who require regular purification, as well as for purification procedures in certain non-critical conditions. Compared to hospitals, clinical environments differ in terms of facility scale and emergency response capabilities. However, for extracorporeal hemoperfusion therapies that can be implemented under outpatient conditions—such as addressing chronic toxic metabolite accumulation or alleviating refractory uremic symptoms—the adsorber serves as a consumable compatible with dialysis machines and tubing systems, offering patients adsorption-based purification functions beyond conventional treatments. Clinics typically house such equipment within blood purification centers or dialysis centers, staffed by trained nurses and physicians who administer hemoperfusion therapy according to standardized operating protocols. Concurrently, integrated with dialysis treatment workflows, strict aseptic and anticoagulation management requirements are adhered to, ensuring the safety and continuity of the purification therapy. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com Email: global@qyresearch.com